These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 6266430)

  • 21. In vitro activity of moxalactam against pathogenic bacteria and its comparison with other antibiotics.
    Perrymann F; Flournoy DJ; Qadri SM
    Chemotherapy; 1983; 29(1):37-42. PubMed ID: 6219865
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative in vitro evaluation of BMY-28142, a new broad-spectrum cephalosporin, versus other beta-lactams against multiresistant gram-negative isolates.
    Giamarellou H; Sahin A; Chryssouli Z
    Drugs Exp Clin Res; 1987; 13(3):149-53. PubMed ID: 3622243
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative activity of cefotaxime and selected beta-lactam antibiotics against Haemophilus influenzae and aerobic gram-negative bacilli.
    Dabernat HJ; Delmas C
    Rev Infect Dis; 1982; 4 Suppl():S401-5. PubMed ID: 6294790
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [In vitro activity of cefotaxime, latamoxef and ceftriaxone on hospital strains of Enterobacteriaceae resistant to cefalotine and cefoxitine].
    Berche P; Gaillard JL
    Ann Biol Clin (Paris); 1986; 44(6):624-7. PubMed ID: 3826779
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibitory and bactericidal activity of cefmetazole and seven other beta-lactams against different bacterial inocula.
    Esposito S; Galante D; Barba D
    Chemioterapia; 1986 Apr; 5(2):101-4. PubMed ID: 3518963
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Effect of multiresistance on the minimal inhibitory concentration of N-formimidoyl thienamycin and 6 comparing substances against P. aeruginosa and 4 Enterobacteriaceae species].
    Schröter G; Schrettenbrunner A; Strenzel I
    Zentralbl Bakteriol Mikrobiol Hyg A Med Mikrobiol Infekt Parasitol; 1983 Feb; 253(4):531-43. PubMed ID: 6407236
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro activity of N-formimidoyl thienamycin in comparison with cefotaxime, moxalactam, and ceftazidime.
    Verbist L; Verhaegen J
    Antimicrob Agents Chemother; 1981 Mar; 19(3):402-6. PubMed ID: 6264844
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative in vitro activity of moxalactam, cefotaxime, cefoperazone, piperacillin, and aminoglycosides against gram-negative bacilli.
    Kurtz TO; Winston DJ; Hindler JA; Young LS; Hewitt WL; Martin WJ
    Antimicrob Agents Chemother; 1980 Oct; 18(4):645-8. PubMed ID: 6255864
    [TBL] [Abstract][Full Text] [Related]  

  • 29. N-Formimidoyl thienamycin (MK0787): in-vitro antibacterial activity and susceptibility to beta-lactamases compared with that of cefotaxime, moxalactam and other beta-lactam antibiotics.
    Hanslo D; King A; Shannon K; Warren C; Phillips I
    J Antimicrob Chemother; 1981 Jun; 7(6):607-17. PubMed ID: 6265426
    [No Abstract]   [Full Text] [Related]  

  • 30. In vitro antimicrobial activity and beta-lactamase stability of moxalactam, a new 1-oxa-cephalosporin.
    Blandino G; Speciale A; Torrisi A; Russo G
    Chemioterapia; 1984 Apr; 3(2):108-15. PubMed ID: 6335837
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Concentration-dependency of beta-lactam-induced filament formation in Gram-negative bacteria.
    Buijs J; Dofferhoff AS; Mouton JW; Wagenvoort JH; van der Meer JW
    Clin Microbiol Infect; 2008 Apr; 14(4):344-9. PubMed ID: 18261128
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro killing of parenteral beta-lactams against standard and high inocula of extended-spectrum beta-lactamase and non-ESBL producing Klebsiella pneumoniae.
    Burgess DS; Hall RG
    Diagn Microbiol Infect Dis; 2004 May; 49(1):41-6. PubMed ID: 15135499
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Susceptibility testing accuracy of a CTX-M-type extended-spectrum beta-lactamase organism-producing population of Enterobacteriaceae: intermethod analysis for 9 beta-lactams.
    Pottumarthy S; Yu Y; Sader HS; Jones RN; Chen M
    Diagn Microbiol Infect Dis; 2005 Oct; 53(2):131-41. PubMed ID: 15939566
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antimicrobial activity and spectrum of cefoperazone against recent clinical isolates.
    Jones RN; Fuchs PC; Barry AL; Gavan TL; Gerlach EH; Sommers HM
    Clin Ther; 1980; 3(Spec Issue):14-23. PubMed ID: 6446389
    [No Abstract]   [Full Text] [Related]  

  • 35. Comparative in vitro activity of 1-oxa-beta-lactam (LY127935) and cefoperazone with other beta-lactam antibiotics against anaerobic bacteria.
    Borobio MV; Aznar J; Jimenez R; Garcia F; Perea EJ
    Antimicrob Agents Chemother; 1980 Feb; 17(2):129-31. PubMed ID: 6247966
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In-vitro activity of the novel oxa-beta-lactam antibiotic moxalactam (LY 127935) against dense populations of selected Gram-negative bacilli.
    Greenwood D; Eley A; Pearson N; O'Grady F
    J Antimicrob Chemother; 1981 Apr; 7(4):353-62. PubMed ID: 6265424
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative in vitro studies of Ro 13-9904, a new cephalosporin derivative.
    Eickhoff TC; Ehret J
    Antimicrob Agents Chemother; 1981 Mar; 19(3):435-42. PubMed ID: 6264845
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Minimal inhibitory and bactericidal concentrations of cefoperazone, cefotaxime, cefuroxime and cefalotin against 90 bacterial strains].
    Mascellino MT; Prignano G; Iegri F; Lorenzi A
    Boll Ist Sieroter Milan; 1982; 61(4):309-19. PubMed ID: 6100234
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro activity of temocillin, moxalactam and cefotaxime against gram negative bacteria sensitive or resistant to ureidopenicillins and/or cefacedone.
    Bartmann K; Tarbuc R
    Zentralbl Bakteriol Mikrobiol Hyg A; 1983 Dec; 256(2):202-10. PubMed ID: 6324518
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reevaluation of Enterobacteriaceae MIC/disk diffusion zone diameter regression scattergrams for 9 beta-lactams: adjustments of breakpoints for strains producing extended spectrum beta-lactamases.
    Jones RN; Craig WA; Ambrose PG; Dudley MN; Pottumarthy S
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):235-46. PubMed ID: 16105568
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.